Compared to RPMI8226, a multiple myeloma cell line that relies on c-MYC for survival (Tagde et al., 2016), we failed to observe suppression of c-MYC protein levels following bortezomib or MLN2238 treatment (Figure 4—figure supplement 1d). The gene discussed is MYC; the disease is AL amyloidosis.